Lipocine Inc
LPCN4.250USD
+0.050+1.19%
收盘 12/19, 16:00（美东）报价延迟15分钟
23.04M总市值
亏损市盈率 TTM
关于 Lipocine Inc 公司
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Inc简介
公司代码LPCN
公司名称Lipocine Inc
上市日期Mar 21, 2014
CEOPatel (Mahesh V)
员工数量16
证券类型Ordinary Share
年结日Mar 21
公司地址675 S Arapeen Dr Ste 202
城市SALT LAKE CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编84108-1295
电话18019947383
网址https://www.lipocine.com/
公司代码LPCN
上市日期Mar 21, 2014
CEOPatel (Mahesh V)
Lipocine Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
4.00%
Patel (Mahesh V)
1.96%
BlackRock Institutional Trust Company, N.A.
1.61%
Geode Capital Management, L.L.C.
1.10%
Susquehanna International Group, LLP
0.84%
其他
90.49%
持股股东
持股股东
占比
The Vanguard Group, Inc.
4.00%
Patel (Mahesh V)
1.96%
BlackRock Institutional Trust Company, N.A.
1.61%
Geode Capital Management, L.L.C.
1.10%
Susquehanna International Group, LLP
0.84%
其他
90.49%
股东类型
持股股东
占比
Investment Advisor
6.76%
Individual Investor
2.84%
Investment Advisor/Hedge Fund
1.89%
Hedge Fund
0.93%
其他
87.58%
机构持股
更新时间: 10月5日 周日
更新时间: 10月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q3
32
528.39K
9.52%
-40.19K
2025Q2
44
680.47K
12.56%
-41.55K
2025Q1
65
678.55K
12.68%
-110.89K
2024Q4
72
645.33K
12.07%
-219.30K
2024Q3
75
703.77K
13.16%
-136.61K
2024Q2
79
690.86K
12.92%
-132.01K
2024Q1
82
639.82K
12.02%
-214.82K
2023Q4
86
649.80K
12.29%
-222.39K
2023Q3
91
667.07K
12.61%
-176.35K
2023Q2
93
641.50K
12.32%
-239.33K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
224.88K
4.15%
-1.40K
-0.62%
Jun 30, 2025
Patel (Mahesh V)
109.05K
2.01%
+1.63K
+1.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
89.27K
1.65%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
61.08K
1.13%
+2.24K
+3.81%
Jun 30, 2025
Susquehanna International Group, LLP
46.02K
0.85%
+7.04K
+18.06%
Jun 30, 2025
Higuchi (John W)
40.80K
0.75%
--
--
Mar 31, 2025
Renaissance Technologies LLC
34.80K
0.64%
-2.71K
-7.23%
Jun 30, 2025
State Street Investment Management (US)
18.63K
0.34%
--
--
Jun 30, 2025
Northern Trust Investments, Inc.
13.16K
0.24%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
公告日期
类型
比率
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
常见问题
Lipocine Inc的前五大股东是谁？
Lipocine Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：224.88K，占总股份比例：4.15%。
Patel (Mahesh V)持有股份：109.05K，占总股份比例：2.01%。
BlackRock Institutional Trust Company, N.A.持有股份：89.27K，占总股份比例：1.65%。
Geode Capital Management, L.L.C.持有股份：61.08K，占总股份比例：1.13%。
Susquehanna International Group, LLP持有股份：46.02K，占总股份比例：0.85%。
The Vanguard Group, Inc.持有股份：224.88K，占总股份比例：4.15%。
Patel (Mahesh V)持有股份：109.05K，占总股份比例：2.01%。
BlackRock Institutional Trust Company, N.A.持有股份：89.27K，占总股份比例：1.65%。
Geode Capital Management, L.L.C.持有股份：61.08K，占总股份比例：1.13%。
Susquehanna International Group, LLP持有股份：46.02K，占总股份比例：0.85%。
Lipocine Inc的前三大股东类型是什么？
Lipocine Inc 的前三大股东类型分别是：
The Vanguard Group, Inc.
Patel (Mahesh V)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Patel (Mahesh V)
BlackRock Institutional Trust Company, N.A.
有多少机构持有Lipocine Inc(LPCN)的股份？
截至2025Q3，共有32家机构持有Lipocine Inc的股份，合计持有的股份价值约为528.39K，占公司总股份的9.52%。与2025Q2相比，机构持股有所增加，增幅为-3.04%。
哪个业务部门对Lipocine Inc的收入贡献最大？
在--，--业务部门对Lipocine Inc的收入贡献最大，创收--，占总收入的--%。
